• Open Access

Gaining the hard yard: pre-clinical evaluation of lentiviral-mediated gene therapy for the treatment of β-thalassemia

Authors

  • Michael D. Milsom,

    1. Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Boston, MA, USA
    2. Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • David A. Williams

    Corresponding author
    1. Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Boston, MA, USA
    2. Harvard Medical School, Boston, MA, USA
    3. Harvard Stem Cell Institute, Boston, MA, USA
    4. Dana Farber Cancer Institute, Brookline, MA, USA
    • Tel: +1-617-919-2027; Fax: +1-617-730-0934

    Search for more papers by this author

Abstract

Gene therapy is one potential novel therapeutic avenue for the treatment of inherited monogenic disorders. Diseases of the blood are frequent targets for gene therapy because it is relatively easy to harvest haematopoietic stem cells (HSCs) from the bone marrow, genetically modify the cells ex vivo, and then re-administer the corrected cells back into the patient via intra-venous injection. In this Closeup, Milsom and Williams discuss the work of Roselli et al, who describe the pre-clinical evaluation of the treatment for β-thalassemia in erythroid cells via the genetic correction of patient HSCs using a lentiviral vector.

See related article in EMBO Mol Med (Roselli et al. (2010) EMBO Mol Med 2: 315–328)

Ancillary